Summary
What do they do? Berkeley Addiction Treatment Services, Inc., EIN 94-2832154, is a separate nonprofit from BAART's treatment network. The official clinic describes methadone maintenance, withdrawal management, counseling and screening. Contra Costa County's February 2026 directory lists adult patients age 18+, methadone/buprenorphine services, Drug Medi-Cal certification, acceptance of new beneficiaries and capacity of 165 at its Berkeley location. These are service eligibility and capacity disclosures, not a measured age distribution, residency census or utilization count. More
Why this approach interests us
- Additional retained medication treatment can reduce mortality among adults with opioid use disorder.
Our main reservations
- Capacity is not observed treatment volume. Existing service revenue and substantial unrestricted cash challenge donation additionality. Local treatment time, alternatives and survival remain assumptions.
What do you get for your dollar?
The signed prior-weighted model gives $36.29 million per 10 Bay QALYs for a hypothetical $10,000 whole-organization gift. The central world is $97.92 million. This is an unfavorable accounting-based hypothesis, not a measured local effect or purchasable return. Inspect the model, assumptions and scenarios.
- bay whole gift
- $36.29M — per 10 modeled Bay QALYs; mortality scope only
- central world
- $97.92M — per 10 Bay QALYs
- favorable world
- $1.90M — 5% subjective weight; not a funding offer
- tail dependence
- 95.58% — of signed expectation from favorable world
- funding room
- Unknown — No verified marginal tranche
1. What do they do?
Berkeley Addiction Treatment Services, Inc., EIN 94-2832154, is a separate nonprofit from BAART's treatment network. The official clinic describes methadone maintenance, withdrawal management, counseling and screening. Contra Costa County's February 2026 directory lists adult patients age 18+, methadone/buprenorphine services, Drug Medi-Cal certification, acceptance of new beneficiaries and capacity of 165 at its Berkeley location. These are service eligibility and capacity disclosures, not a measured age distribution, residency census or utilization count.
Retain all organizational spending
Use $1,371,759 FYJune2025 total expense, including administration and unquantified work; do not price only medicines or subtract reimbursements.
Model occupied treatment-years
165 concurrent slots times an assumed occupancy fraction, not 165 observed unique patients or donor-available places.
Apply separate counterfactuals
Access additionality discounts medication time otherwise supplied by BATS or alternatives. Funding additionality discounts gifts replacing existing resources.
Count finite net Bay health
Transfer an observational mortality association cautiously, subtract signed incremental transition risk, and apply finite survival and Bay-residence judgments.
Scope of this review. Whole historical organizational cash cost; partial mortality benefits. External clinical care, patient travel/time and additional public resources are not assumed free. Complete-resource and verified marginal prices remain null. No separate overdose benefit is added to all-cause mortality.
2. Monitoring and information sharing
Whole legal recipient EIN94-2832154
Filed FYJune2025 IRS990. $1,371,759 expense; service fees$2,811,794; cash$3,006,182.
Our assessment. Retain all cost; nonrecurringERC/interest not ordinary revenue. Financial surplus challenges but does not disprove marginal room.
Adults18+ seeking opioid treatment; Contra Costa Medi-Cal access
County provider directory, February2026. BATS listed as accepting beneficiaries, Drug Medi-Cal certified, capacity165.
Our assessment. Capacity and eligibility are not observed occupancy, age distribution or Bay-residence proportion.
Methadone and buprenorphine treatment cohorts assembled beforeSeptember2016
Original systematic review/meta-analysis of19 observational cohorts. In/out all-cause rates11.3/36.1 and4.3/9.5 deaths per1,000person-years, respectively.
Our assessment. Nonrandom treatment entry/exit, time-varying confounding and induction/cessation risks limit causal transport. Finite survival is separately assumed; no extra overdose credit.
3. Qualitative assessment
Additional retained medication treatment can reduce mortality among adults with opioid use disorder.
Key reservations
- Observed retained-treatment time and medication mix are unavailable; occupied slot-years are assumed.
- No patient-age distribution or precise Bay residence data were located. Adult18+ eligibility is not an age-mix estimate.
- Substantial cash and service reimbursement materially weaken unrestricted donor additionality.
- Historical observational mortality is not a contemporary Bay causal effect; induction and discontinuation can harm.
- The favorable world supplies95.58% of signed expected benefit despite only5% weight.
- Partner, payer and patient incremental resources remain unpriced. No recommendation follows from this partial model.
Benefits not included in our estimate
- Morbidity and quality-of-life improvement during treatment
- Infection prevention and other medical care
- Crime, earnings and family spillovers
- Separate overdose mortality atop all-cause mortality
- Unbounded lifetime survival
4. What do you get for your dollar?
$36,290,155 per 10 modeled Bay QALYs
The $10,000 diagnostic gift represents a share of whole historical expense. Slot occupancy, medication mix, access and funding additionality, mortality causal transfer, future survival and Bay residence are explicit analyst judgments, not observed BATS outcomes. First-run coefficients are preserved.
A better life is our comparison unit of 10 additional quality-adjusted life years (QALYs), potentially spread across people. These are uncertain estimates, not measured returns or verified donation offers.
How we calculate the estimate
SIGNED EXPECTATION BEFORE DIVISION: 10 × $10,000 / 0.002755568302228597 Bay QALYs
$36,290,154.70932942 per 10 Bay QALYs
Model inputs and assumptions
- Whole annual expense
- $1,371,759 (range: FY July2024–June2025). Filed IRS return: $894,339 programme plus $477,420 administration. No netted event cost add-back found. High historical.
- Concurrent capacity
- 165 slots (range: Not an observed patient count). February2026 directory; age18+ and accepting new beneficiaries. No occupancy or dose-day ledger published. County-listed capacity.
- Occupied slot-years
- 75% (range: 50–100%). Central123.75 treatment-years; assumes a fixed165-slot footprint for one year, not annual turnover counted as full years. Judgment.
- Methadone share
- 80% (range: 50–100%). Clinic emphasizes methadone; county also lists buprenorphine. No measured medication mix. Judgment.
- Mortality association
- 0.0248 / 0.0052 per year (range: Methadone / buprenorphine). Difference between pooled out-of-treatment and in-treatment all-cause mortality rates, not randomized causal effects or current Bay rates. External observational evidence.
- Causal mortality transfer
- 45% (range: 0–70%). Accounts for confounding, selection and different patients, care and drug environment; no fentanyl multiplier. Judgment.
- Access additionality
- 30% (range: 10–60%). Equivalent treatment time otherwise obtainable through this or another provider must not be attributed to the gift. Judgment.
- Funding additionality
- 10% (range: 0–50%). Low central prior given service revenue above cost and unrestricted reserves; neither financial fact proves zero current need. Judgment.
- Finite survival
- 10-year horizon (range: 5–20 years). Central93% annual survival,0.70utility and3%discount produce4.319489514249647 QALYs per modeled death averted. No local age/lifespan distribution was measured. Judgment.
- Additional transition risk
- 0.0002 per added year (range: 0–0.003). Extra induction/discontinuation risk beyond the source's average comparison; not a second subtraction of ordinary treatment deaths. Signed judgment.
- Bay-resident share
- 95% (range: 85–100%). Berkeley clinic and Contra Costa access support Bay concentration, not an exact residence proportion. Applied to both signs. Judgment.
- Joint-world weights
- 55% null;10% harm (range: 15% cautious;15% central;5% favorable). Locked before first execution. Not confidence intervals or probabilities medication itself fails. Uncalibrated prior.
$10,000 unrestricted diagnostic — not a quoted package
- Funding null (40%): 0 Bay QALY. No additional delivery.
- Clinical null (15%): 0 Bay QALY. No modeled mortality gain or harm.
- Harm (10%): −0.0003331700301708075 Bay QALY. Retained in expectation; no positive bargain price.
- Cautious (15%): $7.615B per 10. 0.000013131690340720065 Bay QALY.
- Central (15%): $97,916,608.81414448 per 10. 0.0010212771991502485 Bay QALY;0.027063791817658934 additional treatment-years.
- Favorable (5%): $1,898,452.5536823655 per 10. 0.05267447943644065 Bay QALY; full occupancy,60% access,50% funding,70% transfer and20-year horizon.
- Favorable access and funding both100%: Approximately $569,536 per 10. Mechanical3.33×output stress, not a new estimate; precisely the counterfactual most challenged by current financial and access evidence.
Uncertainty. Exact signed Bay expectation0.002755568302228597 QALYs/$10,000; price$36,290,154.70932942/10. Favorable share0.9557825039909112. No declared world beats$1M/10, but the non-exhaustive scenario set cannot exclude unmodeled opportunities. No morbidity, cognitive, infection, crime or family-benefit credit. The model enforces finite5–20year scenario horizons and a0–$10,000 gift domain; neither establishes marginal absorptive capacity.
5. Funding and previous grants
HOLD giving. Obtain dose-days, current cash commitments and a specific unfunded access or retention opportunity.
FYJune2025 revenue$3,187,442 includes$2,811,794 service fees and$375,648 nonrecurring employee-retention-credit refund/interest. Excluding the latter, fees exceed expenses by$1,440,035. Cash$3,006,182; all$3,211,834 net assets unrestricted; liabilities$323,134. Unknown future commitments/recoupment risks prevent equating reserves with free cash. No verified marginal donor package or complete-resource price.
This review does not establish a verified marginal funding offer or a complete history of grants.
We have not verified a suitable donation route for this reviewed activity. Confirm the legal recipient and intended allocation before donating.
6. Sources
- BATS Form990, FY ending June30,2025. IRS via ProPublica. Primary financial filing. Published: Submitted February25,2026; retrieved: 2026-09-11.
- BATS ScheduleO. IRS via ProPublica. Primary filing supplement. Published: Submitted February25,2026; retrieved: 2026-09-11.
- Official services and identity. Berkeley Addiction Treatment Services. Primary provider description. Published: Undated; retrieved: 2026-09-11.
- DMC-ODS Provider Directory, BATS page43. Contra Costa Health. Primary county directory. Published: February1,2026; retrieved: 2026-09-11.
- Mortality risk during and after opioid substitution treatment. Sordo et al., BMJ. Original cohort evidence synthesis. Published: April26,2017; retrieved: 2026-09-11.
- Full-text XML of Sordo et al.. Europe PMC. Original article full text mirror. Published: 2017; retrieved: 2026-09-11.
Annual expenses: years and sources
Average annual expenses (three consecutive fiscal years): $1,123,822. Organization size is separate from the modeled cost-effectiveness of a donation.
Berkeley Addiction Treatment Services
Form 990/990-EZ reported whole-entity expenses; includes program, administration and fundraising costs, but excludes any costs netted against revenue.
Latest original return and prior-year comparative combined with earlier filing data.